Penumbra, Inc. (PEN)

NYSE: PEN · Delayed Price · USD
144.51
-6.31 (-4.18%)
At close: May 18, 2022 4:00 PM
143.66
-0.85 (-0.59%)
Pre-market:May 19, 2022 4:09 AM EDT
Market Cap5.44B
Revenue (ttm)782.28M
Net Income (ttm)-6.47M
Shares Out37.68M
EPS (ttm)0.14
PE Ratio1,032.21
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume397,154
Open147.92
Previous Close150.82
Day's Range143.27 - 150.00
52-Week Range130.96 - 293.20
Beta0.46
AnalystsBuy
Price Target263.67 (+82.5%)
Earnings DateMay 3, 2022

About PEN

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the...

IndustryHealth Care Equipment & Supplies
IPO DateSep 18, 2015
CEOAdam Elsesser
Employees3,800
Stock ExchangeNYSE
Ticker SymbolPEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is 263.67, which is an increase of 82.46% from the latest price.

Price Target
$263.67
(82.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why

Penumbra Inc (NYSE: PEN) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance.  Wells Fargo lowered the price target to $265 from 321, whi...

2 weeks ago - Benzinga

Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Penumbra, Inc. Reports First Quarter 2022 Financial Results

ALAMEDA, Calif. , May 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March ...

2 weeks ago - PRNewsWire

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Penumbra, Inc. to Present at the Bank of America Securities 2022 Healthcare Conference

ALAMEDA, Calif. , April 26, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare Conference ...

3 weeks ago - PRNewsWire

Penumbra Announces the European Launch of the Indigo® System With Lightning™ 7 and Lightning 12 Intelligent Aspiration

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc.'s Indigo Aspiration System with Lightning 7 and Lightning 12 have secured CE Mark and are now commercially available in Europe.

1 month ago - Business Wire

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

These companies have a history of creating shareholder value -- and still have plenty of room for growth.

Other symbols:KIDSOMCL
1 month ago - The Motley Fool

Penumbra, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 3, 2022

ALAMEDA, Calif. , April 5, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2022 after market close ...

1 month ago - PRNewsWire

Penumbra Introduces Next Generation REAL® y-Series™, Expanding Virtual Reality Healthcare Platform

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc. introduces the REAL® Immersive System y-Series™ with significantly more activities and experiences.

1 month ago - Business Wire

Penumbra, Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference

ALAMEDA, Calif. , March 28, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on M...

1 month ago - PRNewsWire

These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022

Looking for small healthcare companies with huge revenue opportunities? Try these.

Other symbols:CLOVVIR
1 month ago - The Motley Fool

Down 16% In A Month, Will Penumbra Stock Rebound?

The stock price of Penumbra, a medical devices company focused on interventional therapies, has seen a 16% fall in a month, while it was down 10% last week. The company reported mixed Q4 results last mo...

2 months ago - Forbes

Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22%

Penumbra Inc (NYSE: PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales of vascular products grew 30.4% (3...

2 months ago - Benzinga

Wall Street Analysts Believe Penumbra (PEN) Could Rally 40%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Penumbra (PEN). While the effectiveness of this highly sought-after metric is questionable, the positive...

2 months ago - Zacks Investment Research

Penumbra (PEN) Q4 Earnings Lag Estimates

Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full y...

2 months ago - PRNewsWire

Earnings Preview: Penumbra (PEN) Q4 Earnings Expected to Decline

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Penumbra, Inc. to Present at Citi's 2022 Virtual Healthcare Conference

ALAMEDA, Calif., Feb. 10, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2022 Virtual Healthcare Conference on Thursday, Febru...

3 months ago - PRNewsWire

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 22, 2022

ALAMEDA, Calif., Feb. 1, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2021 after ...

3 months ago - PRNewsWire

Penumbra Weighing Combination With Shockwave Medical: Bloomberg

Penumbra Inc (NYSE: PEN) is exploring a potential deal with Shockwave Medical Inc (NASDAQ: SWAV), Bloomberg reported citing people with knowledge of the matter. According to the people, Penumbra has hel...

Other symbols:SWAV
4 months ago - Benzinga

Penumbra, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

ALAMEDA, Calif., Dec. 22, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40th Annual J.P.

4 months ago - PRNewsWire

Penumbra's Thrombectomy System Shows Safety, Clinical Benefit

Penumbra Inc (NYSE: PEN) announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter met the primary endpoint. As part of the Indigo Aspiration System, the Indigo CAT RX Aspiration Ca...

6 months ago - Benzinga

New Data Demonstrates Safety and Performance of Continuous Aspiration Thrombectomy with Penumbra's Indigo® System CAT...

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #mechanicalthrombectomy--CHEETAH study demonstrates safety and performance of continuous aspiration thrombectomy for coronary blood clots with Penumbra's Indigo...

6 months ago - Business Wire

Penumbra (PEN) Lags Q3 Earnings Estimates

Penumbra (PEN) delivered earnings and revenue surprises of -14.29% and 4.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Penumbra, Inc. Reports Third Quarter 2021 Financial Results

ALAMEDA, Calif., Nov. 3, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended Septem...

6 months ago - PRNewsWire